Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Homology MedicinesBioDelivery Sciences InternationalSpruce BiosciencesCorMedixFulcrum Therapeutics
SymbolNASDAQ:FIXXNASDAQ:BDSINASDAQ:SPRBNYSEAMERICAN:CRMDNASDAQ:FULC
Price Information
Current Price$7.17$3.50$16.13$9.37$11.51
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.62.11.61.21.7
Analysis Score3.43.43.53.54.3
Community Score2.53.03.92.52.5
Dividend Score0.00.00.00.00.0
Ownership Score1.71.70.00.01.7
Earnings & Valuation Score0.62.50.60.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$27.86$8.15$33.25$19.30$19.00
% Upside from Price Target288.52% upside132.86% upside106.14% upside105.98% upside65.07% upside
Trade Information
Market Cap$362.00 million$353.02 million$375.86 million$356.29 million$376.06 million
Beta-0.240.72N/A2.710.94
Average Volume509,6291,257,58645,2231,221,822141,899
Sales & Book Value
Annual Revenue$1.67 million$111.39 millionN/A$280,000.00N/A
Price / Sales216.773.17N/A1,272.45N/A
CashflowN/A$0.14 per shareN/A$0.25 per shareN/A
Price / CashN/A24.16N/A37.85N/A
Book Value$5.73 per share$0.78 per shareN/A$0.92 per share$3.73 per share
Price / Book1.254.49N/A10.18N/A
Profitability
Net Income$-103,920,000.00$-15,310,000.00N/A$-16,430,000.00$-82,680,000.00
EPS($2.47)$0.10N/A($0.89)($8.13)
Trailing P/E RatioN/A25.000.00N/AN/A
Forward P/E RatioN/A9.21N/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-5,386.00%10.16%N/A-10,214.42%N/A
Return on Equity (ROE)-57.92%25.04%N/A-86.52%-71.94%
Return on Assets (ROA)-45.33%9.89%N/A-70.16%-56.24%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.82%N/AN/AN/A
Current Ratio10.55%3.16%7.30%8.45%4.99%
Quick Ratio10.55%2.80%7.30%8.40%4.99%
Ownership Information
Institutional Ownership Percentage75.20%67.40%N/A25.91%72.52%
Insider Ownership Percentage33.40%8.57%N/A5.00%30.30%
Miscellaneous
Employees206176173073
Shares Outstanding50.49 million100.86 million23.30 million38.02 million32.67 million
Next Earnings Date5/6/2021 (Estimated)5/6/2021 (Estimated)6/28/2021 (Estimated)5/10/2021 (Estimated)5/12/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableOptionableNot Optionable
SourceHeadline
Fulcrum Therapeutics (NASDAQ:FULC) Given "Buy" Rating at HC WainwrightFulcrum Therapeutics (NASDAQ:FULC) Given "Buy" Rating at HC Wainwright
americanbankingnews.com - April 12 at 8:30 AM
Bicycle Wheels Market Giants Spending Is Going To Boom | Easton Cycling, Boyd Cycling, Pro LiteBicycle Wheels Market Giants Spending Is Going To Boom | Easton Cycling, Boyd Cycling, Pro Lite
industribune.net - April 11 at 10:23 PM
Sickle cell disease: scientists are developing a game-changing treatmentSickle cell disease: scientists are developing a game-changing treatment
sciencefocus.com - April 10 at 9:12 AM
Toward a transformative therapy for sickle cell patientsToward a transformative therapy for sickle cell patients
news-medical.net - April 10 at 9:12 AM
Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at ...Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at ...
apnews.com - April 9 at 6:04 PM
Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual ConferenceFulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference
finance.yahoo.com - April 9 at 6:04 PM
Fulcrum Therapeutics (NASDAQ:FULC) Coverage Initiated by Analysts at Credit Suisse GroupFulcrum Therapeutics (NASDAQ:FULC) Coverage Initiated by Analysts at Credit Suisse Group
americanbankingnews.com - March 29 at 9:28 AM
Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and DevelopmentFulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development
finance.yahoo.com - March 24 at 10:53 AM
Fulcrum Therapeutics (NASDAQ:FULC) Now Covered by Analysts at Credit Suisse GroupFulcrum Therapeutics (NASDAQ:FULC) Now Covered by Analysts at Credit Suisse Group
americanbankingnews.com - March 22 at 9:04 AM
Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome ...Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome ...
apnews.com - March 18 at 1:02 PM
Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific ConferenceFulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference
finance.yahoo.com - March 18 at 1:02 PM
Morgan Stanley Increases Fulcrum Therapeutics (NASDAQ:FULC) Price Target to $12.00Morgan Stanley Increases Fulcrum Therapeutics (NASDAQ:FULC) Price Target to $12.00
marketbeat.com - March 15 at 8:37 AM
Fulcrum Therapeutics Inc Registered Shs Equal WeightFulcrum Therapeutics Inc Registered Shs Equal Weight
markets.businessinsider.com - March 10 at 1:23 PM
Morgan Stanley Maintains Equal-Weight on Fulcrum Therapeutics, Raises Price Target to $12Morgan Stanley Maintains Equal-Weight on Fulcrum Therapeutics, Raises Price Target to $12
benzinga.com - March 8 at 6:30 PM
X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q4 2020 Results - Earnings Call TranscriptX4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - March 5 at 5:30 PM
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 ...Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 ...
apnews.com - March 5 at 2:28 AM
Fulcrum Therapeutics Inc Registered Shs BuyFulcrum Therapeutics Inc Registered Shs Buy
markets.businessinsider.com - March 4 at 9:27 PM
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue EstimatesFulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates
finance.yahoo.com - March 4 at 1:40 PM
Fulcrum Therapeutics Inc to Host Earnings CallFulcrum Therapeutics Inc to Host Earnings Call
finance.yahoo.com - March 4 at 8:39 AM
Fulcrum Therapeutics Announces CEO TransitionFulcrum Therapeutics Announces CEO Transition
finance.yahoo.com - March 4 at 8:39 AM
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial ResultsFulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 4 at 8:39 AM
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference ...Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference ...
apnews.com - February 27 at 3:13 AM
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ETFulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ET
finance.yahoo.com - February 26 at 7:11 AM
Fulcrum Therapeutics Recognizes Rare Disease Day 2021Fulcrum Therapeutics Recognizes Rare Disease Day 2021
finance.yahoo.com - February 26 at 7:11 AM
What Type Of Shareholders Own The Most Number of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares?What Type Of Shareholders Own The Most Number of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares?
finance.yahoo.com - February 17 at 1:32 PM
Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by ...Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by ...
apnews.com - January 22 at 7:43 PM
DateCompanyBrokerageAction
3/8/2021Homology MedicinesStifel NicolausInitiated Coverage
12/14/2020Homology MedicinesHC WainwrightReiterated Rating
8/11/2020Homology MedicinesOppenheimerLower Price Target
8/10/2020Homology MedicinesChardan CapitalReiterated Rating
6/25/2020Homology MedicinesBank of AmericaInitiated Coverage
6/25/2020Homology MedicinesFIXInitiated Coverage
5/13/2020Homology MedicinesRoyal Bank of CanadaInitiated Coverage
3/13/2020Homology MedicinesRobert W. BairdBoost Price Target
7/26/2019Homology MedicinesCanaccord GenuitySet Price Target
4/11/2019Homology MedicinesEvercore ISIInitiated Coverage
5/25/2020BioDelivery Sciences InternationalPiper SandlerReiterated Rating
5/25/2020BioDelivery Sciences InternationalCantor FitzgeraldReiterated Rating
5/25/2020BioDelivery Sciences InternationalRoth CapitalReiterated Rating
4/22/2020BioDelivery Sciences InternationalNorthland SecuritiesInitiated Coverage
12/18/2019BioDelivery Sciences InternationalSunTrust BanksBoost Price Target
11/13/2019BioDelivery Sciences InternationalLADENBURG THALM/SH SHBoost Price Target
11/13/2019BioDelivery Sciences InternationalJanney Montgomery ScottReiterated Rating
9/17/2019BioDelivery Sciences InternationalWilliam BlairReiterated Rating
3/29/2021Spruce BiosciencesCredit Suisse GroupLower Price Target
11/3/2020Spruce BiosciencesSVB LeerinkInitiated Coverage
11/3/2020Spruce BiosciencesCowenInitiated Coverage
3/2/2021CorMedixB. RileyReiterated Rating
2/17/2021CorMedixNeedham & Company LLCInitiated Coverage
9/29/2020CorMedixJMP SecuritiesInitiated Coverage
9/21/2020CorMedixTruistInitiated Coverage
3/15/2021Fulcrum TherapeuticsMorgan StanleyBoost Price Target
8/12/2020Fulcrum TherapeuticsBTIG ResearchLower Price Target
6/17/2020Fulcrum TherapeuticsRaymond JamesUpgrade
(Data available from 4/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.